comparemela.com

Latest Breaking News On - Infectious diseases vaccines - Page 3 : comparemela.com

Janssen: New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma

Phase 1b results of teclistamab in combination with DARZALEX? (daratumumab) subcutaneous (SC) also presented at ASH 2021 Annual Meeting1,2 The Janssen Pharmaceutical Companies of Johnson Johnson

United statesNoah reymondYusri elsayedEdmond chan mbchPhilippe moreauJessica mooreJanssen biotech incAmerican society of hematology annual meetingAmerican society of clinical oncologyCancer research instituteDrugs take center stage in myelomaJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyUniversity hospital

Janssen: New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma

Data presented at ASH 2021 congress show 83 percent of patients achieved a stringent complete response at median follow-up of 22 months1 92 percent of evaluable patients achieved minimal residual

United statesCiltacabtagene autoleucelNoah reymondEdmond chan mbchThomas martinSen zhuangJessica mooreMyeloma programJanssen biotech incAmerican society of clinical oncologyAmerican society of hematology annual meetingJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyClinical research

Janssen: New Clinical and Real-World Data Support Use of DARZALEX? (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma

Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world evidence

United statesNoah reymondEdmond chan mbchJacob laubachJessica mooreImran khanAmerican society of clinical oncologyJanssen biotech incAmerican society of hematology annual meetingJerome lipper multiple myeloma centerJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyJanssen scientific affairsDana farber cancer instituteAmerican cancer society

Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT ? (amivantamab), the First Treatment Approved for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

For EU Trade and Medical Media Only. Not to Be Distributed to UK and Benelux Based Media Conditional Marketing Authorisation is based on results from the Phase 1 CHRYSALIS study evaluating amivantamab

United kingdomNoah reymondPeter lebowitzJessica mooreSarah jonesMathai mammenAntonio passaroNone of the janssen pharmaceutical companiesJanssen biotech incEuropean commissionDrug administrationJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonJanssen research developmentExchange commissionEuropean union

Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy

If approved by the European Commission, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced non-small cell lung cancer

United statesUnited kingdomNoah reymondJennifer mcintyrePeter lebowitzCatherine taylorSarah jonesJanssen biotech incAmerican society of clinical oncologyJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAffairs therapeutic area strategyEuropean unionCommittee for medicinal products human useNone of the janssen pharmaceutical companies

vimarsana © 2020. All Rights Reserved.